Collaborators at the UW O’Brien Center and Vanderbilt University Medical Center describe prostaglandin activation in patients who fail medical therapy for BPH/LUTS.

Collaborators at the UW O’Brien Center and Vanderbilt University Medical Center describe prostaglandin activation in patients who fail medical therapy for BPH/LUTS. The new publication in The Prostate demonstrates that treatment of BPH/LUTS by inhibition of alpha-adrenergic receptors with pharmaceutical alpha-blockers or inhibiting androgenesis with 5ARI may fail because of elevated paracrine signaling by prostatic prostaglandins that can cause smooth muscle contraction. See the full publication here: https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.24190

Leave a Reply

Your email address will not be published.